» Articles » PMID: 8981339

Effect of Estrogen Replacement Therapy on Natural Killer Cell Activity in Postmenopausal Women

Overview
Journal Maturitas
Specialty Geriatrics
Date 1996 Nov 1
PMID 8981339
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate the impact of menopause and estradiol substitution on natural killer cell activity.

Methods: Natural killer cell activity and antibody-dependent cellular cytotoxicity were measured in peripheral blood of 53 postmenopausal and 20 premenopausal women in an interval of 3 weeks. Postmenopausal patients were randomly assigned to receive either estradiol valerate (2 mg daily) orally (n = 18), estradiol (50 micrograms/24 h) transcutaneously (n = 18) or no substitution (n = 17), and the testing was repeated 3 weeks later.

Results: Natural killer cell activity but not antibody-dependent cellular cytotoxicity was significantly (P < 0.01) higher in unsubstituted postmenopausal compared to premenopausal subjects. Natural killer cell activity decreased both in orally and transcutaneously estradiol-treated patients (mean [S.D.] before vs. after 3 weeks; oral: 60.8 [9.2]% vs. 52.8 [8.2]% P < 0.01; transcutaneous: 61.5 [10.6]% vs. 54.3 [9.1]% P < 0.01; no substitution: 60.6 [10.6]% vs. 59.3 [8.9]% P > 0.1), whereas antibody-dependent cellular cytotoxicity showed no changes. The addition of 0.1 to 10 ng/ml estradiol to peripheral blood mononuclear cells of untreated postmenopausal women in vitro had no influence upon natural killer cell activity.

Conclusion: Postmenopausal women receiving no estrogen replacement exhibited an increased natural killer cell activity which decreased during estrogen substitution.

Citing Articles

The Tumor Immune Microenvironment in Breast Cancer Progression.

Otterlei Fjortoft M, Huse K, Rye I Acta Oncol. 2024; 63:359-367.

PMID: 38779867 PMC: 11332517. DOI: 10.2340/1651-226X.2024.33008.


Impact of menopause on relapse rate and disability level in patients with multiple sclerosis (MS): a systematic review and meta-analysis.

Shahraki Z, Rastkar M, Rastkar E, Mohammadifar M, Mohamadi A, Ghajarzadeh M BMC Neurol. 2023; 23(1):316.

PMID: 37667181 PMC: 10476298. DOI: 10.1186/s12883-023-03332-1.


Estrogen, the Peripheral Immune System and Major Depression - A Reproductive Lifespan Perspective.

Engler-Chiurazzi E, Chastain W, Citron K, Lambert L, Kikkeri D, Shrestha S Front Behav Neurosci. 2022; 16:850623.

PMID: 35493954 PMC: 9051447. DOI: 10.3389/fnbeh.2022.850623.


More than just a pretty face? The relationship between immune function and perceived facial attractiveness.

Mengelkoch S, Gassen J, Prokosch M, Boehm G, Hill S Proc Biol Sci. 2022; 289(1969):20212476.

PMID: 35168398 PMC: 8848230. DOI: 10.1098/rspb.2021.2476.


Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.

Jang S, Nikita N, Banks J, Keith S, Johnson J, Wilson M JAMA Netw Open. 2021; 4(12):e2136823.

PMID: 34854905 PMC: 8640892. DOI: 10.1001/jamanetworkopen.2021.36823.